Fulcrum Therapeutics Reports $26.2 Million Net Loss and Workforce Reduction Amid Restructuring

Fulcrum Therapeutics, Inc. reported significant financial challenges in its latest quarterly filing, revealing a net loss of $26.2 million for the three months ended June 30, 2026, compared to a loss of $17.3 million for the same period in 2025. For the first half of 2026, the company recorded a net loss of $45.1 million, up from $35.0 million in the prior year. The increase in losses is attributed to higher operating expenses, which totaled $29.3 million for the second quarter, a 47.9% increase from $19.8 million in the same quarter of 2025. The company's accumulated deficit now stands at $639.3 million.

The financial report highlights a substantial restructuring effort initiated by the company, which included a workforce reduction of approximately 85%, from 57 employees to just nine. This decision followed the discontinuation of the pociredir program for sickle cell disease, prompted by unfavorable feedback from the U.S. Food and Drug Administration regarding the drug's benefit-risk profile. The restructuring plan, approved on May 31, 2026, aims to significantly reduce operating expenses and preserve capital, with the company also ceasing all research and development activities.

In terms of cash flow, Fulcrum reported $318.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, a decrease from $366.3 million at the end of 2025. The company experienced a net cash outflow of $34.8 million from operating activities during the first half of 2026, compared to $29.1 million in the same period of 2025. The increase in cash used in operations is primarily due to the higher net loss. Additionally, the company reported a net cash outflow of $114.4 million from investing activities, largely due to increased purchases of marketable securities.

Looking ahead, Fulcrum has engaged Leerink Partners LLC to assist in a comprehensive review of strategic alternatives, which may include mergers, acquisitions, or asset sales. The company has not set a timeline for this review, and there is no guarantee that it will result in a successful transaction. Fulcrum's management believes that its current cash reserves will be sufficient to fund operations for at least the next 12 months, although this estimate is contingent on various factors, including the outcome of the strategic review and ongoing operational costs.